{"filing":{"accession_number":"0001193125-26-430860","cik":"0001861123","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"eikn-20261026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526430860/eikn-20261026.htm"},"events":[{"id":37729,"run_id":34771,"accession_number":"0001193125-26-430860","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Eikon disclosed updated clinical trial data from the Phase 2 TeLuRide-005 trial of EIK1001 in advanced NSCLC, presented at ESMO Congress on October 26, 2026. The data demonstrated efficacy (63.1% ORR and 89.2% DCR in the pooled population; 72.4% ORR and 100% DCR in the squamous cohort with 12.9-month median duration of response) and a favorable safety profile supporting outpatient administration, representing a material operational milestone supporting advancement toward the Phase 2/3 TeLuRide-008 trial.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42533,"accession_number":"0001193125-26-430860","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Eikon disclosed updated clinical trial data from TeLuRide-005 showing EIK1001 efficacy and safety results presented at ESMO Congress. This is a material operational/clinical milestone for a late-stage biopharmaceutical company—the squamous cohort achieved 72% ORR and 100% DCR with 12.9-month median duration of response, supporting advancement toward the Phase 2/3 TeLuRide-008 trial. While not a specific earnings release or M\u0026A event, the positive clinical data represents a significant operational development affecting investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:52.834109+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42534,"accession_number":"0001193125-26-430860","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports updated clinical trial data from the TeLuRide-005 Phase 2 trial of EIK1001 in advanced NSCLC, presented at ESMO Congress on October 26, 2026. The data demonstrates efficacy (63.1% ORR, 89.2% DCR in pooled population; 72.4% ORR in squamous cohort) and a favorable safety profile supporting outpatient administration. While this is a clinical milestone for a late-stage biopharmaceutical company, it does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, or other named event types. As a material operational/strategic development affecting investor assessment of the company's lead product candidate's therapeutic potential and regulatory pathway, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:52.834109+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42533,"accession_number":"0001193125-26-430860","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Eikon disclosed updated clinical trial data from TeLuRide-005 showing EIK1001 efficacy and safety results presented at ESMO Congress. This is a material operational/clinical milestone for a late-stage biopharmaceutical company—the squamous cohort achieved 72% ORR and 100% DCR with 12.9-month median duration of response, supporting advancement toward the Phase 2/3 TeLuRide-008 trial. While not a specific earnings release or M\u0026A event, the positive clinical data represents a significant operational development affecting investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:52.834109+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-26"},{"id":42534,"accession_number":"0001193125-26-430860","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports updated clinical trial data from the TeLuRide-005 Phase 2 trial of EIK1001 in advanced NSCLC, presented at ESMO Congress on October 26, 2026. The data demonstrates efficacy (63.1% ORR, 89.2% DCR in pooled population; 72.4% ORR in squamous cohort) and a favorable safety profile supporting outpatient administration. While this is a clinical milestone for a late-stage biopharmaceutical company, it does not fit the specific categories of earnings release, exec changes, M\u0026A, restatement, or other named event types. As a material operational/strategic development affecting investor assessment of the company's lead product candidate's therapeutic potential and regulatory pathway, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:52.834109+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-26"}]}
